Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life …

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic interstitial pneumonia
with unknown causes. The incidence rate increases year by year and the prognosis is poor …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease (ILD) of unknown aetiology, with a median survival of 2–4 years from the time of …

Idiopathic pulmonary fibrosis (IPF) is a progressive and fibrosing lung disease with a poor
prognosis. Between 60% and 70% of IPF patients die of IPF; the remaining causes of death …

Immune checkpoint inhibitors are novel agents that have been proved efficacious in a
variety of cancer types, but they are associated with a unique set of organ-specific, immune …

Pulmonary fibrosis is a fatal lung disease for which no effective treatment is available.
Previous studies have shown that the expression of programmed cell death-Ligand (PD-L1) …

Patients with idiopathic pulmonary fibrosis (IPF) have a high risk of developing lung cancer
compared with the general population. The morbidity of lung cancer in IPF patient ranges …

The prognosis of lung cancer is poor with few effective therapies. Targeting ferroptosis is a
new promising strategy for cancer therapy. LINC00641 has been involved in several …

Idiopathic pulmonary fibrosis (IPF) affects an increasing number of people globally, yet
treatment options remain limited. At present, conventional treatments depending on drug …

Idiopathic pulmonary fibrosis (IPF) is the most devastating progressive interstitial lung
disease that remains refractory to treatment. Pathogenesis of IPF relies on the aberrant cross …